LENSAR (LENSAR) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is LENSAR Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of LENSAR is: No Data: Cannot be evaluated.

Competitive Comparison of LENSAR's Risk Assessment

For the Medical Devices subindustry, LENSAR's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LENSAR's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LENSAR's Risk Assessment distribution charts can be found below:

* The bar in red indicates where LENSAR's Risk Assessment falls into.

LENSAR (NAS:LNSR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

LENSAR Risk Assessment Related Terms

Thank you for viewing the detailed overview of LENSAR's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

LENSAR (LENSAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LENSAR Inc (NAS:LNSR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

2800 Discovery Drive, Orlando, FL, USA, 32826

Website

https://www.lensar.com

LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Aimee S Weisner	director	ONE EDWARDS WAY, IRVINE CA 92614
Nr-gri Partners Gp, Llc	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Nr-gri Partners, Lp	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Todd B Hammer	director, 10 percent owner	NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116
Thomas B Ellis	director, 10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
North Run Advisors, Llc	10 percent owner	62 WALNUT STREET, WELLESLEY MA 02481
North Run Capital, Lp	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Staab Thomas R Ii	officer: Chief Financial Officer	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Kendra Wong	officer: Principal Accounting Officer	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Alan B. Connaughton	officer: Chief Operating Officer	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Nicholas T Curtis	director, officer: Chief Executive Officer	C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016
Pdl Biopharma, Inc.	10 percent owner	59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391